Intern
    Onkologische Forschung

    Michael Hudecek: CAR T-cell Engineering

    Summary

    Our group is working in the field of tumor immunology and our efforts are directed at the development and clinical translation of adoptive immunotherapy of cancer with tumor-specific T cells. A recent focus in the lab is the engineering of T cells that have been modified by gene transfer to express tumor-targeting chimeric antigen receptors (CARs). CARs are synthetic receptors with an extracellular antigen-binding domain derived from the variable heavy and light chains of a monoclonal antibody and an intracellular signaling module that mediates T-cell activation after antigen-binding. We are working on defining target molecules that are expressed on malignant cells but not on vital normal tissues and can be targeted by CAR T cells, and deriving insights into how to best design these receptors in order to confer optimum tumor recognition and T-cell activation. 

    Recent Publications

    Receptor affinity and extracellular domain modifications affect tumor-recognition by ROR1-specific chimeric antigen receptor T cells. Hudecek M, Lupo-Stanghellini MT, Kosasih P, Sommermeyer D, Jensen MC, Rader C, Riddell SR. Clin Cancer Res. 2013 Jun 15;19(12):3153-3164.

    The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR. Blood. 2010 Nov 25;116(22):4532.

    Adoptive T-cell therapy for B-cell malignancies. Hudecek M, Anderson LD Jr, Nishida T, Riddell SR. Expert Rev Hematol. 2009 Oct;2(5):517-32.

    Kontakt

    Comprehensive Cancer Center
    Haus C16
    Josef-Schneider Str. 6
    97080 Würzburg

    Tel.: +49 931 201-35350
    Fax: +49 931 201-35359
    E-Mail

    Suche Ansprechpartner

    Campus Medizin